These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33140850)

  • 1. Developing cell therapies as drug products.
    Ciccocioppo R; Comoli P; Astori G; Del Bufalo F; Prapa M; Dominici M; Locatelli F
    Br J Pharmacol; 2021 Jan; 178(2):262-279. PubMed ID: 33140850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?
    Schäfer R
    BMC Med; 2019 Mar; 17(1):53. PubMed ID: 30832655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient.
    López-Beas J; Guadix JA; Clares B; Soriano-Ruiz JL; Zugaza JL; Gálvez-Martín P
    Med Res Rev; 2020 Jul; 40(4):1315-1334. PubMed ID: 32017179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What is established in cell therapies? : Possibilities and limits in immuno-oncology].
    Quaiser A; Köhl U
    Internist (Berl); 2018 Dec; 59(12):1230-1238. PubMed ID: 30367191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
    Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
    [No Abstract]   [Full Text] [Related]  

  • 8. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
    Lowdell MW; Thomas A
    Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
    Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
    Acta Oncol; 2001; 40(2-3):135-54. PubMed ID: 11441927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results.
    Hossein-Khannazer N; Torabi S; Hosseinzadeh R; Shahrokh S; Asadzadeh Aghdaei H; Memarnejadian A; Kadri N; Vosough M
    Hum Cell; 2021 Sep; 34(5):1289-1300. PubMed ID: 34057700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.
    Wu X; Jiang J; Gu Z; Zhang J; Chen Y; Liu X
    Stem Cell Res Ther; 2020 Aug; 11(1):345. PubMed ID: 32771052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerising cellular therapies: what is their promise for autoimmune disease?
    Mosanya CH; Isaacs JD
    Ann Rheum Dis; 2019 Mar; 78(3):297-310. PubMed ID: 30389690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal Stromal Cells for Transplant Tolerance.
    Podestà MA; Remuzzi G; Casiraghi F
    Front Immunol; 2019; 10():1287. PubMed ID: 31231393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
    Mahalatchimy A; De Grove-Valdeyron N
    J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically modified T cells in cancer therapy: opportunities and challenges.
    Sharpe M; Mount N
    Dis Model Mech; 2015 Apr; 8(4):337-50. PubMed ID: 26035842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stromal cells for osteonecrosis.
    Elgaz S; Bonig H; Bader P
    J Transl Med; 2020 Oct; 18(1):399. PubMed ID: 33081809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mesenchymal stem/stromal cells. Its therapeutic potential in medicine].
    Domínguez LM; Fiore EJ; Mazzolini GD
    Medicina (B Aires); 2020; 80(6):696-702. PubMed ID: 33254115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.